Oncologic outcomes after adjuvant chemotherapy with capecitabine compared to 5-fluorouracil/leucovorin for geriatric stage II colon cancer: a retrospective cohort study

被引：0
|
作者：
Kil-yong Lee
Ji Won Park
Ki-young Lee
Sangsik Cho
Yoon-Hye Kwon
Min Jung Kim
Seung-Bum Ryoo
Seung-Yong Jeong
Kyu Joo Park
机构：
[1] Seoul National University College of Medicine,Department of Surgery
[2] Seoul National University College of Medicine,Cancer Research Institute
来源：
International Journal of Colorectal Disease | 2019年 / 34卷
关键词：
Geriatric patients; Colon cancer; Stage II; Capecitabine; 5-Fluorouracil/leucovorin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：629 / 639
页数：10
相关论文
共 50 条
  • [1] Oncologic outcomes after adjuvant chemotherapy with capecitabine compared to 5-fluorouracil/leucovorin for geriatric stage II colon cancer: a retrospective cohort study
    Lee, Kil-yong
    Park, Ji Won
    Lee, Ki-young
    Cho, Sangsik
    Kwon, Yoon-Hye
    Kim, Min Jung
    Ryoo, Seung-Bum
    Jeong, Seung-Yong
    Park, Kyu Joo
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2019, 34 (04) : 629 - 639
  • [2] Adjuvant chemotherapy in stage III colon cancer with 5-fluorouracil and levamisole versus 5-fluorouracil and leucovorin
    Dencausse, Y
    Hartung, G
    Sturm, J
    Kopp-Schneider, A
    Hagmüller, E
    Wojatschek, C
    Lindemann, H
    Fritze, D
    Queisser, W
    ONKOLOGIE, 2002, 25 (05): : 426 - 430
  • [3] Benefit of adjuvant 5-fluorouracil based chemotherapy for colon cancer: a retrospective cohort study
    Mondaca, Sebastian
    Villalon, Constanza
    Luis Leal, Jose
    Zuniga, Alvaro
    Bellolio, Felipe
    Padilla, Oslando
    Palma, Silvia
    Garrido, Marcelo
    Nervi, Bruno
    REVISTA MEDICA DE CHILE, 2016, 144 (02) : 145 - 151
  • [4] 5-Fluorouracil/leucovorin versus capecitabine in patients with stage III colon cancer
    Seitz, JF
    SEMINARS IN ONCOLOGY, 2001, 28 (01) : 41 - 44
  • [5] A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer
    W Schippinger
    H Samonigg
    R Schaberl-Moser
    R Greil
    R Thödtmann
    J Tschmelitsch
    M Jagoditsch
    G G Steger
    R Jakesz
    F Herbst
    F Hofbauer
    H Rabl
    P Wohlmuth
    M Gnant
    J Thaler
    British Journal of Cancer, 2007, 97 : 1021 - 1027
  • [6] Pharmacoeconomic Analysis of Capecitabine versus 5-Fluorouracil/Leucovorin as Adjuvant Therapy for Stage III Colon Cancer in Taiwan
    Hsu, Tzu-Chi
    Chen, Hong-Hwa
    Yang, Ming-Chin
    Wang, Hwei-Ming
    Chuang, Jye-Hann
    Jao, Shu-Wen
    Chiang, Hsin-Chieh
    Wen, Chung-Yu
    Tseng, Jen-Hao
    Chen, Li-Tzong
    VALUE IN HEALTH, 2011, 14 (05) : 647 - 651
  • [7] A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer
    Schippinger, W.
    Samonigg, H.
    Schaberl-Moser, R.
    Greil, R.
    Thoedtmann, R.
    Tschmelitsch, J.
    Jagoditsch, M.
    Steger, G. G.
    Jakesz, R.
    Herbst, F.
    Hofbauer, F.
    Rabl, H.
    Wohlmuth, P.
    Gnant, M.
    Thaler, J.
    BRITISH JOURNAL OF CANCER, 2007, 97 (08) : 1021 - 1027
  • [8] Adjuvant systemic chemotherapy with 5-fluorouracil and leucovorin in colon cancer: A monoinstitutional institutional experience
    Jirillo, Antonio
    Stefani, Michaela
    Vascon, Federica
    Lonardi, Sara
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2008, 30 (02) : 235 - 242
  • [9] Adjuvant 5-Fluorouracil/leucovorin, capecitabine, and oxaliplatin-related regimens for stage II/III colon cancer patients 66 years or older
    Jones, Emily
    Duan, Zhigang
    Nguyen, Thinh T.
    Giordano, Sharon H.
    Zhao, Hui
    CANCER MEDICINE, 2023, 12 (03): : 2389 - 2406
  • [10] Oncologic Outcomes of Oral Adjuvant Chemotherapy Regimens in Stage III Colon Cancer: Tegafure-Uracil Plus Leucovorin Versus Capecitabine
    Tashiro, Jo
    Yamaguchi, Shigeki
    Ishii, Toshimasa
    Kondo, Hiroka
    Hara, Kiyoka
    Shimizu, Hiroki
    Takemoto, Kenichi
    Suzuki, Asami
    CLINICAL COLORECTAL CANCER, 2017, 16 (03) : E141 - E145
12345